Atlas Trials

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

Clinical trial NCT02538510 · COMPLETED

Trial details

NCT number
NCT02538510
Sponsor
University of Washington
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Head and Neck Squamous Cell CarcinomaRecurrent Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaRecurrent Nasopharynx CarcinomaRecurrent Salivary Gland CarcinomaSquamous Cell Carcinoma Metastatic in the Neck With Occult PrimaryStage III Major Salivary Gland CarcinomaStage III Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage III Nasopharyngeal CarcinomaStage IV Nasopharyngeal CarcinomaStage IVA Major Salivary Gland CarcinomaStage IVA Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage IVB Major Salivary Gland Carcinoma
Start date
2015-10-08
Primary completion
2019-09-28
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.